On the stock market since 2007, it operates in the world of health and science. It has 27 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 81% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $10.9M. In times of high interest rates, a gap like that can squeeze a company.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 3,967% — that slice of every sale is the company’s cushion in hard quarters.
The stock sits at $0.17. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales fell about 86% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 3645 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, TBGNF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TBGNF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.